AlphaQuest LLC Takes Position in ASP Isotopes Inc. $ASPI

AlphaQuest LLC purchased a new position in shares of ASP Isotopes Inc. (NASDAQ:ASPI) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 34,716 shares of the company’s stock, valued at approximately $256,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the company. Exchange Traded Concepts LLC bought a new stake in shares of ASP Isotopes during the 2nd quarter valued at $9,593,000. Harbour Capital Advisors LLC bought a new position in shares of ASP Isotopes in the second quarter worth $232,000. Philadelphia Financial Management of San Francisco LLC raised its stake in ASP Isotopes by 11.2% in the first quarter. Philadelphia Financial Management of San Francisco LLC now owns 3,508,062 shares of the company’s stock valued at $16,453,000 after purchasing an additional 354,517 shares in the last quarter. AWM Investment Company Inc. lifted its position in ASP Isotopes by 6.2% during the first quarter. AWM Investment Company Inc. now owns 4,511,186 shares of the company’s stock worth $21,157,000 after purchasing an additional 265,000 shares during the period. Finally, Farther Finance Advisors LLC bought a new stake in ASP Isotopes during the second quarter worth about $707,000. 16.80% of the stock is owned by institutional investors.

ASP Isotopes Stock Down 5.8%

Shares of NASDAQ ASPI opened at $10.14 on Friday. The company has a 50 day simple moving average of $9.81 and a 200 day simple moving average of $8.54. The company has a debt-to-equity ratio of 3.53, a current ratio of 14.72 and a quick ratio of 14.56. ASP Isotopes Inc. has a 1 year low of $3.65 and a 1 year high of $14.49. The firm has a market cap of $947.18 million, a PE ratio of -7.98 and a beta of 3.29.

ASP Isotopes (NASDAQ:ASPI) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($1.03) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.92). The business had revenue of $1.20 million during the quarter, compared to the consensus estimate of $1.60 million. ASP Isotopes had a negative return on equity of 239.22% and a negative net margin of 2,181.62%. On average, research analysts forecast that ASP Isotopes Inc. will post -0.24 EPS for the current year.

Insider Activity at ASP Isotopes

In other ASP Isotopes news, CEO Robert Ainscow sold 22,500 shares of the stock in a transaction that occurred on Tuesday, October 14th. The shares were sold at an average price of $13.60, for a total transaction of $306,000.00. Following the completion of the sale, the chief executive officer owned 1,647,193 shares of the company’s stock, valued at approximately $22,401,824.80. This represents a 1.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Paul Elliot Mann sold 81,077 shares of ASP Isotopes stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $8.39, for a total transaction of $680,236.03. Following the transaction, the chief executive officer directly owned 8,084,191 shares of the company’s stock, valued at $67,826,362.49. This represents a 0.99% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 406,199 shares of company stock valued at $3,718,977 over the last ninety days. Insiders own 21.40% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on ASPI shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ASP Isotopes in a report on Thursday. Canaccord Genuity Group restated a “buy” rating and set a $11.00 price objective on shares of ASP Isotopes in a research report on Wednesday, September 17th. Finally, Loop Capital set a $15.00 target price on ASP Isotopes in a research note on Monday, October 27th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, ASP Isotopes has a consensus rating of “Hold” and a consensus target price of $13.00.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.